
    
      This study was designed to prospectively randomized, controlled, double-blind study.This
      method of recruitment patients who undergo resection or biopsy of glioblastoma (newly
      diagnosed glioblastoma), immediately after diagnosis, patients will receive an explanation
      about the study and sign a consent form will enter research.

      Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma),
      will randomization ratio of 1: 1 by the pharmacist (by age, Karnofsky score, the degree of
      tumor resection) two research groups:

      Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg
      Cymbalta morning for a week and then a dose exceeding 60 mg for 3 months.

      Group # 2: will include 50 patients treated immediately after diagnosis placebo for 3 months.
    
  